Sam Halabi, J.D., M.Phil., Richard Wilder, J.D., Lawrence O. Gostin, J.D., and Maria Luisa Hurtado, L.L.B.
doi : 10.1056/NEJMp2304214
Vol. 388 No. 26
Ashley Woodcock, M.D.
doi : 10.1056/NEJMp2302197
Jacob T. Elberg, J.D., Eli Y. Adashi, M.D., and I. Glenn Cohen, J.D.
doi : 10.1056/NEJMp2303535
Urs Fischer, M.D., Masatoshi Koga, M.D., Ph.D., Daniel Strbian, Ph.D., Mattia Branca, Ph.D., Stefanie Abend, B.Sc., Sven Trelle, M.D., Maurizio Paciaroni, M.D., Götz Thomalla, M.D., Patrik Michel, M.D., Krassen Nedeltchev, M.D., Leo H. Bonati, M.D., George Ntaios, M.D., Thomas Gattringer, Ph.D., Else-Charlotte Sandset, Ph.D., Peter Kelly, M.D., Robin Lemmens, Ph.D., P.N. Sylaja, M.D., Diana Aguiar de Sousa, Ph.D., Natan M. Bornstein, M.D., Zuzana Gdovinova, M.D., Ph.D., Takeshi Yoshimoto, M.D., Ph.D., Marjaana Tiainen, M.D., Ph.D., Helen Thomas, R.N., Manju Krishnan, M.B., B.S., Gek C. Shim, M.B., B.Ch., Christoph Gumbinger, M.D., Jochen Vehoff, M.D., Liqun Zhang, M.D., Ph.D., Kosuke Matsuzono, M.D., Ph.D., Espen Kristoffersen, M.D., Ph.D., Philippe Desfontaines, M.D., Peter Vanacker, M.D., Ph.D., Angelika Alonso, M.D., Yusuke Yakushiji, M.D., Ph.D., Caterina Kulyk, M.D., Dimitri Hemelsoet, M.D., Sven Poli, M.D., Ana Paiva Nunes, M.D., Nicoletta Caracciolo, M.D., Peter Slade, M.B., B.Ch., Jelle Demeestere, M.D., Ph.D., Alexander Salerno, M.D., Markus Kneihsl, M.D., Ph.D., Timo Kahles, M.D., Daria Giudici, M.D., Kanta Tanaka, M.D., Ph.D., Silja Räty, M.D., Ph.D., Rea Hidalgo, R.N., David J. Werring, F.R.C.P., Ph.D., Martina Göldlin, M.D., Marcel Arnold, M.D., Cecilia Ferrari, M.B.A.-I.H.M., Seraina Beyeler, Ph.D., Christian Fung, M.D., Bruno J. Weder, M.D., Turgut Tatlisumak, M.D., Ph.D., Sabine Fenzl, M.D., Beata Rezny-Kasprzak, M.D., Arsany Hakim, M.D., Georgia Salanti, Ph.D., Claudio Bassetti, M.D., Jan Gralla, M.D., David J. Seiffge, M.D., Thomas Horvath, M.D., and Jesse Dawson, M.D. for the ELAN Investigators*
doi : 10.1056/NEJMoa2303048
The effect of early as compared with later initiation of direct oral anticoagulants (DOACs) in persons with atrial fibrillation who have had an acute ischemic stroke is unclear.
Emily A. DeBoy, B.S., Michael G. Tassia, Ph.D., Kristen E. Schratz, M.D., Stephanie M. Yan, B.A., Zoe L. Cosner, M.D., Emily J. McNally, B.S., Dustin L. Gable, M.D., Ph.D., Zhimin Xiang, M.B., B.S., David B. Lombard, M.D., Ph.D., Emmanuel S. Antonarakis, M.D., Christopher D. Gocke, M.D., Rajiv C. McCoy, Ph.D., and Mary Armanios, M.D.
doi : 10.1056/NEJMoa2300503
Telomere shortening is a well-characterized cellular aging mechanism, and short telomere syndromes cause age-related disease. However, whether long telomere length is advantageous is poorly understood.
Nicholas P. Deputy, Ph.D., Joseph Deckert, Ph.D., Anna N. Chard, Ph.D., Neil Sandberg, M.S., Danielle L. Moulia, M.P.H., Eric Barkley, B.S., Alexandra F. Dalton, Ph.D., Cory Sweet, M.S., Amanda C. Cohn, M.D., David R. Little, M.D., Adam L. Cohen, M.D., Danessa Sandmann, M.P.H., Daniel C. Payne, Ph.D., Jacqueline L. Gerhart, M.D., and Leora R. Feldstein, Ph.D.
doi : 10.1056/NEJMoa2215201
In the United States, more than 30,000 cases of mpox (formerly known as monkeypox) had occurred as of March 1, 2023, in an outbreak disproportionately affecting transgender persons and gay, bisexual, and other men who have sex with men. In 2019, the JYNNEOS vaccine was approved for subcutaneous administration (0.5 ml per dose) to prevent mpox infection. On August 9, 2022, an emergency use authorization was issued for intradermal administration (0.1 ml per dose); however, real-world effectiveness data are limited for either route.
Geert D’Haens, M.D., Ph.D., Marla Dubinsky, M.D., Taku Kobayashi, M.D., Ph.D., Peter M. Irving, M.D., Stefanie Howaldt, M.D., Juris Pokrotnieks, M.D., Ph.D., Kathryn Krueger, M.D., Janelle Laskowski, Ph.D., Xingyuan Li, Ph.D., Trevor Lissoos, M.D., Joe Milata, B.S.N., Nathan Morris, Ph.D., Vipin Arora, Ph.D., Catherine Milch, M.D., William Sandborn, M.D., and Bruce E. Sands, M.D. for the LUCENT Study Group*
doi : 10.1056/NEJMoa2207940
Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial.
Bruna Gomes, M.D., and Euan A. Ashley, M.B., Ch.B., D.Phil.
doi : 10.1056/NEJMra2204787
Jean-Michel Berenger, and Phillippe Parola, M.D., Ph.D.
doi : 10.1056/NEJMicm2213963
Tara E. Soumerai, M.D., Gregory M. Cote, M.D., Ph.D., Reece J. Goiffon, M.D., Ph.D., Armen I. Yerevanian, M.D., and Albert L. Sy, M.D.
doi : 10.1056/NEJMcpc2300899
Ken Uchino, M.D.
doi : 10.1056/NEJMe2304801
doi : 10.1056/NEJMc2304780
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟